A Multi-Targeted Topical Therapy for Hair Fall Control and Follicular Regeneration
Clinical Evaluation of Safety and Efficacy in Male Subjects with Hair Fall and Early Alopecia.
Hair fall and androgen-related alopecia are among the most prevalent cosmetic and psychosocial conditions affecting adult males globally. Q-HAIRGROWTH Serum is a scientifically engineered, multi-component topical formulation designed to activate hair follicle stem cells (HFSCs), inhibit DHT-mediated follicular miniaturization, reduce oxidative stress, and restore the scalp microenvironment.
A prospective, open-label, single-arm 8-week human clinical study in 40 male subjects aged 25–40 years demonstrated:
The results validate Q-HAIRGROWTH as an advanced non-drug topical therapy for hair fall control and follicular rejuvenation.
HFSC activation, DHT modulation, antioxidant protection, microcirculation support, and follicular repair.
Visible reduction in shedding within the first 7–10 days in most subjects.
Progressive improvements in growth and density trends observed toward Weeks 6–8.
Excellent local tolerability profile with no serious adverse events reported.
Alopecia affects 60–70% of adult males worldwide, with onset frequently beginning between 25–40 years of age. Male pattern hair loss is driven by multifactorial pathophysiology, including:
Androgen signaling contributes to follicular miniaturization.
Reduced growth duration impacts hair shaft output.
Progressive reduction in follicle size and terminal hair production.
Inflammatory scalp environment can impair follicular function.
The Problem with Current Therapies: Conventional approaches often target only one mechanism (e.g., vasodilation or hormonal modulation), resulting in incomplete or transient benefits.
Q-HAIRGROWTH™ was formulated as a multi-pathway biological system designed to restore the follicular ecosystem rather than merely stimulate hair shafts.
Support hair follicle stem cell signaling and re-entry into active growth.
5-α-reductase pathway modulation to reduce miniaturization pressure.
Protect follicles from ROS stress and micro-inflammatory signaling.
Support nutrient delivery and scalp tissue oxygenation.
Nutrient + peptide-driven support for shaft quality and follicle resilience.
This integrated strategy aligns with current advances in hair biology emphasizing HFSC reactivation as the central driver of sustained hair regeneration.
The formula is structured to address complementary pathways involved in hair fall control, follicular regeneration, and scalp homeostasis.
Actives designed to support HFSC signaling, follicular cycling, and anagen re-entry.
Botanical and bioactive components aligned to reduce miniaturization signaling.
Protection against oxidative follicular stress that contributes to shedding.
Barrier function, hydration, and microbiome-friendly scalp balance support.
Prospective, open-label, single-arm study.
40 male subjects, 25–40 years, hair fall / early alopecia.
8 weeks with scheduled evaluations.
Adult males within protocol age limits.
Hair fall with early-stage alopecia indicators.
Willingness to apply product as directed and attend visits.
Recent use of other hair growth therapies that could bias outcomes.
Active dermatologic conditions requiring medical treatment.
| Visit / Timepoint | Assessments |
|---|---|
| Baseline (Week 0) | Enrollment, scalp exam, hair fall baseline, standardized imaging, tolerability check. |
| Week 2 | Hair fall trend, scalp condition review, compliance assessment. |
| Week 4 | Hair density trend, subject self-assessment, tolerability check. |
| Week 6 | New hair growth evaluation, imaging, investigator assessment. |
| Week 8 (End) | Final efficacy + safety evaluation, imaging, overall satisfaction scoring. |
Primary objective: assess safety and hair fall reduction trends with standardized observation across 8 weeks.
Measurements included investigator assessment, standardized photography, subject feedback, and scalp condition tracking.
Reduction in shedding trends over time.
Visible improvements in new growth and density.
Oiliness, irritation, flaking, redness, and comfort.
Local reactions and overall safety observations.
Hair fall reduction trend (replace chart image below with your PDF chart export):
Hair fall reduction begins within ~7–10 days in most subjects.
Approx. 80–95% hair fall control trend by Week 3 (observational).
Progressive improvement in new hair growth and density toward Weeks 6–8.
| Parameter | Observed Trend |
|---|---|
| Scalp Comfort | Improved subjective comfort and reduced irritation trend. |
| Flaking / Redness | Reduced visible signs of dryness and irritation in many subjects. |
| Overall Tolerability | Excellent tolerability profile with no serious adverse events reported. |
Supports follicular cycling signals central to durable regeneration.
Aligns with reduced miniaturization signaling load over time.
Improves local oxidative/inflammatory balance and supports healthier follicle function.
Collectively, outcomes are consistent with a multi-pathway topical strategy rather than a single-target stimulant.
No serious adverse events reported; well tolerated under study conditions.
Designed for consistent topical use with a comfort-forward sensory profile.
Q-HAIRGROWTH™ Serum demonstrated rapid hair fall reduction, progressive improvements in growth and density toward Weeks 6–8, and excellent tolerability. The study supports its positioning as an advanced non-drug topical therapy for hair fall control and follicular rejuvenation.
Advancing scalp and hair biology through multi-pathway topical innovation and clinically guided development.
